论文部分内容阅读
Therapeutic options for the treatment of colorectal cancer(CRC)are diverse but still not always satisfying.Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hypermutated tumors suggests a permanent ro